CNTX · Context Therapeutics Inc.

Cash flow pressures intensified, with net cash provided by operating activities at -$11.4 million and free cash flow at -$11.5 million after modest $37 thousand capital expenditures. These figures illustrate negative cash flows inherent to pre-revenue biotech operations, where funds are directed toward research, development, and clinical trials without committed capital sources or credit facilities. Management notes the inability to precisely forecast capital needs due to uncertainties in pharmaceutical development and commercialization.

Looking forward, the company anticipates continued significant expenses and operating losses as it progresses product candidates through clinical stages toward regulatory approval. General and administrative costs are expected to rise further to support R&D, potential commercialization, and public company overheads. With no revenue and reliance on external financing, Context Therapeutics will need substantial additional capital to sustain operations and execute its growth strategy, emphasizing the urgency of near-term funding amid these investment-driven losses.